2011’s biggest patent expiries

Home/Policies & Legislation | Posted 22/04/2011 post-comment0 Post your comment

2011 looks set to be a bumper year for generics, with patents from some of the biggest selling drugs set to expire.

picture 85

Just looking at the top five selling drugs, US sales of more than US$10 billion will be open to competition by the generics industry.

Key patent expiries, according to data from EvaluatePharma, include Lipitor (atorvastatin – Pfizer), Zyprexa (olanzapine – Eli Lilly), Levaquin (levofloxacin – Johnson & Johnson), Concerta (methylphenidate – Johnson & Johnson) and Protonix (pantoprazole – Pfizer). These patent expiries, while being very good news for the generics industry and patients could deal a major blow to some of the largest pharmaceutical companies.

In 2010, with US$10.8 billion in worldwide sales, Lipitor accounted for 15.8% of Pfizer’s total revenue. While in 2010, Zyprexa’s worldwide revenues were just over US$5 billion, or nearly 22% of Eli Lilly’s full year sales.

Once drugs lose patent protection, lower-price generics rapidly gain market share, often siphoning off as much as 90% of sales. Benefits to patients are substantial, with generics averaging about 30% of the price of the brand-name originals.

Related article

2012’s biggest patent expiries

Source: EvaluatePharma

comment icon Comments (0)
Post your comment
Related content
FDA publishes final Q&A on biosimilar development and the BPCI Act
Question-Fimea-V15E29
Home/Policies & Legislation Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
Home/Policies & Legislation Posted 08/10/2021
USA BIOSIM Act introduction
02 AA010638
Home/Policies & Legislation Posted 17/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010